Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Weintraub, D. Articles by Stern, M. B. Search for Related Content PubMed Citation Articles by Weintraub, D. Articles by Stern, M. B. Depression Parkinson's Disease Antidepressants

Escitalopram for Major Depression in Parkinson’s Disease: An Open-Label, Flexible-Dosage Study

Received April 3, 2005; revised May 19, 2005; accepted June 13, 2005. Drs. Weintraub, Duda, Katz, Stern, and Ms. Taraborelli are affiliated with the University of Pennsylvania School of Medicine and the Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania. Dr. Morales is affiliated with the Department of Biostastics and Epidemiology at the University of Pennsylvania, Philadelphia, Pennsylvania. Address correspondence to Dr. Weintraub, 3535 Market St., Rm. 3003, Philadelphia, PA 19104; weintrau{at}mail.med.upenn.edu (E-mail).

Depression and antidepressant use are common in Parkinson’s disease, but the benefit of selective serotonin reuptake inhibitor (SSRI) treatment in this population has not been established. The authors treated 14 Parkinson’s disease patients with major depression with escitalopram in an open-label study. Although treatment was well tolerated and correlated with a significant decrease in Inventory of Depressive Symptomatology score, response and remission rates were only 21% and 14%, respectively. However, half of the subjects met Clinical Global Impression-Improvement criteria for response. In Parkinson’s disease, either SSRIs may have limited antidepressant effects, or the use of existing depression diagnostic and rating instruments may be problematic.

This article has been cited by other articles:

				M. S. Okun and H. H. Fernandez Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients? Neurology, March 10, 2009; 72(10): 868 - 869. [Full Text] [PDF]

				B. Ravina, R. Camicioli, P. G. Como, L. Marsh, J. Jankovic, D. Weintraub, and J. Elm The impact of depressive symptoms in early Parkinson disease Neurology, July 24, 2007; 69(4): 342 - 347. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us